At CannaKeys, our mission has always been clear: to provide high-quality, evidence-based information that bridges the gap between cannabinoid science and real-world clinical application.
Starting May 2025, we are taking a major step forward to make that mission even stronger.
We’re launching a new, upgraded process for developing our condition synopses—designed to improve clarity, scientific integrity, and clinical usefulness across the entire platform.
Why This Upgrade Matters
In a rapidly evolving field like endocannabinoid medicine, accuracy alone is not enough. Context, clinical experience, and specialty-specific insights are crucial to help users make sense of complex conditions and treatment considerations.
That’s why our new process involves three layers of expert contribution:
- Writing by Ph.D. specialists in endocannabinoid medicine and cannabinoid-based therapeutics.
- Review and updates by practicing physicians to ensure clinical relevance and integration of the latest evidence.
- Specialty review and editing by expert physicians to bring forward nuanced perspectives critical to complex cases.
This new approach ensures that each synopsis is not only scientifically sound but also meaningfully informed by real-world clinical practice.
How Will This Look? Example: Anxiety
As part of our new upgrade, conditions like Anxiety will move beyond generalized summaries toward more structured, clinically nuanced insights. For example, the updated anxiety synopsis will distinguish between Clinical Considerations (Understanding the state of the science, mechanisms, risks, and patient variability), Clinical Implications (Guiding practical use and care strategies), and Evidence-based Key Findings, each with specific guidance on major or minor cannabinoid selections, terpenes, and additional therapeutic strategies focusing on relevant modulators of the endocannabinoidome (eCBome).
This deeper level of clinical insight will help users support optimal endocannabinoid signaling with greater precision, safety, and personalization, reflecting the best of current evidence and real-world specialty experience.
A Systematic Transition Across 300+ Conditions
While the upgraded editorial process will begin rolling out in May 2025, updating all 300+ conditions currently on the CannaKeys platform will take time.
We are fully committed to applying this enhanced methodology systematically and thoughtfully, ensuring every updated synopsis meets the same high standards of:
- Scientific rigor
- Clinical relevance
- Specialty-informed nuance
You’ll start to see updated conditions go live in waves throughout 2025 and beyond.
Thank You for Growing with Us
We are grateful for the trust, engagement, and feedback from our community.
This upgrade is part of our ongoing commitment to being the leading resource for evidence-based cannabinoid insights, grounded in real clinical experience and scientific excellence.
We can’t wait to share the next generation of CannaKeys with you!
— The CannaKeys Team
